| Execution period | Up to December 31, 2030 |
|---|
NSE filing, NSE: KSHINTL. Summary written from the filing by ALFA Finder's alert engine.
KSH International Ltd: key numbers
- Share price
- ₹932.50
- Market cap
- ₹6,318 Cr
- Revenue (annual)
- ₹3,107 Cr
- Net profit (annual)
- ₹110.1 Cr
- P/E (TTM)
- 48.7×Sector 52.2×
- Promoter holding
- 74.58%+0.00% QoQ
- FII holding
- 6.60%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from KSH International Ltd
All →KSH International Business Update
KSH International received PGCIL manufacturer approval to produce CTC, PICC, and BPICC for 765 kV transformers/reactors. The Supa Facility can now supply conductors for POWERGRID projects.
KSH International Board Meeting Date
KSH International will hold a board meeting on November 04, 2026, to consider and approve unaudited financial results for the quarter ended September 30, 2026.
KSH International Management Change
KSH International appointed Mr. Amitabha Mukhopadhyay as an Additional Non-Executive Independent Director. Mr. Ajay Shriram Patil resigned as an Independent Director.
KSH International Annual General Meeting
KSH International Limited held its 47th Annual General Meeting on September 15, 2026, and has submitted the summary of proceedings to the exchange.
KSH International Production Started
KSH International Limited received Consent to Operate from the Maharashtra Pollution Control Board. This approval enables a total manufacturing capacity of 28,800 MTPA at its Supa Facility.
- manufacturing capacity
- 28800.0 MTPA
KSH International Regulatory Approval
KSH International received a 'Consent to Operate' from the Maharashtra Pollution Control Board for its Supa Facility. This approval authorizes a total manufacturing capacity of 28,800 MTPA.
- manufacturing capacity
- 28800.0 MTPA
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.